The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
03-Feb-20
$NA
Target:
Woodward’s renewable power systems and protective relays business
Acquiror:
Aurelius Equity Opportunities
Advised Woodward, a leading designer, manufacturer, and service provider of control solutions for the aerospace and industrial markets, on the divestiture of select assets related to its renewable power systems and protective relays businesses to Aurelius Equity Opportunities
31-Jan-20
Undisclosed
Target:
Wildstone
Acquiror:
Digital Colony
Advised Wildstone, a leading aggregation and digitalization company for outdoor billboards, on its sale to Digital Colony, whilst contemporaneously acquiring Insite Poster Group
19-Dec-19
$770 million
Target:
Wireless Infrastructure Group Limited
Acquiror:
Brookfield Asset Management
Advised 3i Infrastructure plc on the sale of Wireless Infrastructure Group Limited, a leading independent telecommunications infrastructure provider focusing on mobile towers and indoor connectivity
17-Jun-19
$80 million
Target:
Renewi Canada
Acquiror:
Convent Capital
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
07-May-19
$244 million
Target:
FTTH network including 933,000 BU’s
Advising MasMovil, the fourth largest Spanish telecom operator, in the sale of part of its fibre-to-the-home (FTTH) network to an international infrastructure fund. The transaction perimeter includes 933,000 homes across 5 main Spanish cities
19-Dec-18
$NA
Target:
Pfizer Inc. Consumer Health Business
Acquiror:
GlaxoSmithKline plc
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
06-Dec-18
$153 million
Target:
49% of 250MW Concentrated Solar Power ("CSP") portfolio in Spain from ContourGlobal
Acquiror:
Credit Suisse Energy Infrastructure Europe 1
Advised Credit Suisse Energy Infrastructure Partners (“CSEIP”), an investment boutique within the Asset Management business of Credit Suisse AG, on the acquisition of the 49% stake of 250MW Concentrated Solar Power (“CSP”) portfolio in Spain from ContourGlobal, an international owner and operator of contracted wholesale power generation businesses
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
24-Aug-18
$51 million
Target:
Portfolio of 2 wind farms of Grupo Empresarial Enhol
Acquiror:
Quercus European Renewables
Advised Grupo Empresarial Enhol, a leading independent renewable power generator, on the divestment of its controlling stakes in two wind farms located in Spain with a total installed capacity of 48 MW
16-Aug-18
$NA
Target:
Sky plc
Acquiror:
The Walt Disney Company / Twenty-First Century Fox, Inc.
Acted on behalf of a group of independent shareholders of Sky plc, representing their interests at the Hearings Committee of the UK Takeover Panel and at the Takeover Appeals Board in the context of the Panel’s determination of a Chain Principle Offer price payable by Disney for Sky
07-Jun-18
$NA
Target:
Greenpark Aparcamientos
Acquiror:
Parkia
Advised Oak Hill Advisors in the sale of Greenpark Aparcamientos, a leading off-street car park operator, to Parkia, a portfolio company of First State Investments
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
26-Apr-18
$NA
Target:
IslaLink
Acquiror:
Fiera Infrastructure
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
24-Apr-18
$751 million
Target:
Cityfibre Infrastructure Holdings plc
Acquiror:
Antin Infrastructure Partners and West Street Infrastructure Partners
Advised Antin Infrastructure Partners and West Street Infrastructure Partners, part of Goldman Sachs’ Merchant Banking division, in connection with the take private of CityFibre Infrastructure Holdings plc, a leading independent provider of wholesale fibre network infrastructure
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
18-Dec-17
$6.0 billion
Target:
CB&I
Acquiror:
McDermott International, Inc.
Advised McDermott International, Inc., a leading provider of integrated engineering, procurement, construction, installation and module fabrication services for upstream field developments worldwide, on its combination with CB&I, a leading provider of technology and infrastructure for the energy industry
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
11-May-17
$245 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
06-Dec-16
$1.8 billion
Target:
Host Europe Group
Acquiror:
GoDaddy
Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR